JP2022542431A5 - - Google Patents

Info

Publication number
JP2022542431A5
JP2022542431A5 JP2022506359A JP2022506359A JP2022542431A5 JP 2022542431 A5 JP2022542431 A5 JP 2022542431A5 JP 2022506359 A JP2022506359 A JP 2022506359A JP 2022506359 A JP2022506359 A JP 2022506359A JP 2022542431 A5 JP2022542431 A5 JP 2022542431A5
Authority
JP
Japan
Prior art keywords
sequence
seq
variable region
chain variable
multispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542431A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/070334 external-priority patent/WO2021022304A2/en
Publication of JP2022542431A publication Critical patent/JP2022542431A/ja
Publication of JP2022542431A5 publication Critical patent/JP2022542431A5/ja
Pending legal-status Critical Current

Links

JP2022506359A 2019-07-30 2020-07-30 二重特異性抗ｌｒｒｃ１５及びｃｄ３イプシロン抗体 Pending JP2022542431A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962880347P 2019-07-30 2019-07-30
US62/880,347 2019-07-30
PCT/US2020/070334 WO2021022304A2 (en) 2019-07-30 2020-07-30 MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO LRRC15 AND CD3ε

Publications (2)

Publication Number Publication Date
JP2022542431A JP2022542431A (ja) 2022-10-03
JP2022542431A5 true JP2022542431A5 (cg-RX-API-DMAC7.html) 2023-08-08

Family

ID=72145539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506359A Pending JP2022542431A (ja) 2019-07-30 2020-07-30 二重特異性抗ｌｒｒｃ１５及びｃｄ３イプシロン抗体

Country Status (6)

Country Link
US (1) US20230374130A1 (cg-RX-API-DMAC7.html)
EP (1) EP4004050A2 (cg-RX-API-DMAC7.html)
JP (1) JP2022542431A (cg-RX-API-DMAC7.html)
CN (2) CN114341186B (cg-RX-API-DMAC7.html)
CA (1) CA3146341A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021022304A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022253248A1 (zh) * 2021-06-02 2022-12-08 启愈生物技术(上海)有限公司 抗cd3抗体变异体、融合蛋白及应用
CN117940460A (zh) * 2021-09-08 2024-04-26 上海齐鲁制药研究中心有限公司 双特异性抗原结合分子及其应用
CN116253802A (zh) 2021-12-10 2023-06-13 苏州泽璟生物制药股份有限公司 包含lrrc15抗原结合结构域的多特异性t细胞接合剂
WO2024005713A1 (en) * 2022-06-27 2024-01-04 Scg Cell Therapy Pte. Ltd. Bispecific antibodies for hbv surface antigen（hbsag）and cd3 and uses thereof
CA3261708A1 (en) * 2022-08-09 2024-02-15 Qlsf Biotherapeutics, Inc. ANTIBODIES BINDING TO CLEC12A
WO2024081729A2 (en) * 2022-10-12 2024-04-18 Mythic Therapeutics, Inc. Lrrc-15-binding protein constructs and uses thereof
CN120051491A (zh) 2022-11-01 2025-05-27 上海齐鲁制药研究中心有限公司 一种针对磷脂酰肌醇蛋白聚糖3的双特异性抗体及其应用
WO2025064369A1 (en) * 2023-09-18 2025-03-27 Modernatx, Inc. Humanized anti-cd3 binding molecules and uses thereof
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025201242A1 (en) * 2024-03-25 2025-10-02 Tavotek Biotherapeutics (Hong Kong) Limited Antibodies targeting fap and lrrc15 and fusion proteins targeting hyaluronan and uses thereof
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
EP1585768A2 (en) 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US20050239700A1 (en) * 2003-10-14 2005-10-27 Biogen Idec Inc. Treatment of cancer using antibodies to LRRC15
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
PT3904391T (pt) 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
KR102211837B1 (ko) * 2013-01-14 2021-02-03 젠코어 인코포레이티드 신규한 이형이량체 단백질
JP2016514676A (ja) 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
US10259887B2 (en) * 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
DK3310814T5 (da) * 2015-06-16 2024-10-07 Hoffmann La Roche Humaniserede og affinitetsmodnede antistoffer mod FcRH5 og fremgangsmåder til anvendelse
SI3331910T1 (sl) * 2015-08-03 2020-07-31 Engmab Sarl Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
AU2016365114A1 (en) 2015-11-30 2018-05-17 Abbvie Biotherapeutics Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
AU2016365117A1 (en) * 2015-11-30 2018-05-31 Abbvie Biotherapeutics Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
PE20241349A1 (es) * 2016-09-14 2024-07-03 Teneobio Inc Anticuerpos de union a cd3
MY203000A (en) 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins

Similar Documents

Publication Publication Date Title
JP2022542431A5 (cg-RX-API-DMAC7.html)
JP7853992B2 (ja) クローディン１８ａ２及びｃｄ３に対する二重特異性抗体及びその使用
JP7549961B2 (ja) 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット
JP6721590B2 (ja) 多重特異性抗体
JP2023538945A5 (cg-RX-API-DMAC7.html)
JP2021508458A (ja) Ｒｏｒ１特異性抗原結合分子
JP2021534096A5 (cg-RX-API-DMAC7.html)
JP2024532485A5 (cg-RX-API-DMAC7.html)
JP2021512630A5 (cg-RX-API-DMAC7.html)
TW202227491A (zh) 抗ｒｏｒ１抗體及相關雙特異性結合蛋白
JP2023518134A5 (cg-RX-API-DMAC7.html)
JP2020531438A5 (ja) Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質
CN106456760B (zh) 人源化的抗-Tau(pS422)抗体脑穿梭物及其应用
JP2010500876A5 (cg-RX-API-DMAC7.html)
FI3582806T3 (fi) Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja
JP2018503380A5 (cg-RX-API-DMAC7.html)
MX2014000816A (es) Molecula fv de union de antigeno multivalente.
JP2024541048A5 (cg-RX-API-DMAC7.html)
JP2021533159A5 (cg-RX-API-DMAC7.html)
JP7679399B2 (ja) 抗ｆｌｔ３抗体及び組成物
JP2021522347A5 (cg-RX-API-DMAC7.html)
JP2021511782A (ja) 安定化された免疫グロブリンドメイン
JP2020502233A5 (cg-RX-API-DMAC7.html)
JP2021500873A (ja) システイン操作された抗原結合分子
JP2024001073A5 (cg-RX-API-DMAC7.html)